Pamela Trail

Pamela Trail is a leading expert in oncology research and has more than 30 years of experience in the biotechnology and pharmaceutical industry developing ADCs, immunomodulatory antibodies, bispecific antibodies and small molecules.

Between 2017 and 2019, she held the position Chief Scientific Officer at Molecular Partners. Prior, she served as Vice President Oncology Strategy and Program Direction at Regeneron Pharmaceuticals. She also held the positions of Vice President of Oncology Research at MedImmune, Chief Scientific Officer at Seattle Genetics, Global Vice President of Oncology Research at Bayer Healthcare, and Director of Oncology Research at Bristol-Myers Squibb. Dr. Tail has authored over 45 publications and holds multiple issued patents. Dr. Trail has served as a Board Member of BerGen Bio, Nilogen Oncosystems, and Neoantigenics.

She holds a PhD in Immunology from University of Connecticut.